319 related articles for article (PubMed ID: 21194247)
1. A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 2.
Kelly GS
Altern Med Rev; 2010 Dec; 15(4):313-28. PubMed ID: 21194247
[TBL] [Abstract][Full Text] [Related]
2. A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 1.
Kelly G
Altern Med Rev; 2010 Sep; 15(3):245-63. PubMed ID: 21155626
[TBL] [Abstract][Full Text] [Related]
3. Sirtuin activators.
Alcaín FJ; Villalba JM
Expert Opin Ther Pat; 2009 Apr; 19(4):403-14. PubMed ID: 19441923
[TBL] [Abstract][Full Text] [Related]
4. Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases.
Knutson MD; Leeuwenburgh C
Nutr Rev; 2008 Oct; 66(10):591-6. PubMed ID: 18826454
[TBL] [Abstract][Full Text] [Related]
5. The neurobiology of sirtuins and their role in neurodegeneration.
Donmez G
Trends Pharmacol Sci; 2012 Sep; 33(9):494-501. PubMed ID: 22749331
[TBL] [Abstract][Full Text] [Related]
6. [The sirtuin family : regulators that connect metabolism, aging, and longevity].
Imai S
Clin Calcium; 2013 Jan; 23(1):29-38. PubMed ID: 23268299
[TBL] [Abstract][Full Text] [Related]
7. A patent review of sirtuin activators: an update.
Villalba JM; de Cabo R; Alcain FJ
Expert Opin Ther Pat; 2012 Apr; 22(4):355-67. PubMed ID: 22475539
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol--a boon for treating Alzheimer's disease?
Anekonda TS
Brain Res Rev; 2006 Sep; 52(2):316-26. PubMed ID: 16766037
[TBL] [Abstract][Full Text] [Related]
9. Sirtuins: novel targets for metabolic disease.
Elliott PJ; Jirousek M
Curr Opin Investig Drugs; 2008 Apr; 9(4):371-8. PubMed ID: 18393104
[TBL] [Abstract][Full Text] [Related]
10. Mechanism-based modulator discovery for sirtuin-catalyzed deacetylation reaction.
Zheng W
Mini Rev Med Chem; 2013 Jan; 13(1):132-54. PubMed ID: 22876953
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of activators and inhibitors of sirtuins.
Balcerczyk A; Pirola L
Biofactors; 2010; 36(5):383-93. PubMed ID: 20848588
[TBL] [Abstract][Full Text] [Related]
12. After the grape rush: sirtuins as epigenetic drug targets in neurodegenerative disorders.
Huber K; Superti-Furga G
Bioorg Med Chem; 2011 Jun; 19(12):3616-24. PubMed ID: 21306906
[TBL] [Abstract][Full Text] [Related]
13. A possibility of nutriceuticals as an anti-aging intervention: activation of sirtuins by promoting mammalian NAD biosynthesis.
Imai S
Pharmacol Res; 2010 Jul; 62(1):42-7. PubMed ID: 20085812
[TBL] [Abstract][Full Text] [Related]
14. Slowing ageing by design: the rise of NAD
Bonkowski MS; Sinclair DA
Nat Rev Mol Cell Biol; 2016 Nov; 17(11):679-690. PubMed ID: 27552971
[TBL] [Abstract][Full Text] [Related]
15. Sirtuin modulators: an updated patent review (2012 - 2014).
Mellini P; Valente S; Mai A
Expert Opin Ther Pat; 2015 Jan; 25(1):5-15. PubMed ID: 25435179
[TBL] [Abstract][Full Text] [Related]
16. Seven sirtuins for seven deadly diseases of aging.
Morris BJ
Free Radic Biol Med; 2013 Mar; 56():133-71. PubMed ID: 23104101
[TBL] [Abstract][Full Text] [Related]
17. [Sirtuins--modulation of their activity as a novel therapeutic target].
Kucińska M; Piotrowska H; Murias M
Pol Merkur Lekarski; 2010 Mar; 28(165):231-5. PubMed ID: 20815175
[TBL] [Abstract][Full Text] [Related]
18. Sirtuin 1 (SIRT1): the misunderstood HDAC.
Stünkel W; Campbell RM
J Biomol Screen; 2011 Dec; 16(10):1153-69. PubMed ID: 22086720
[TBL] [Abstract][Full Text] [Related]
19. Neuronal protection by sirtuins in Alzheimer's disease.
Anekonda TS; Reddy PH
J Neurochem; 2006 Jan; 96(2):305-13. PubMed ID: 16219030
[TBL] [Abstract][Full Text] [Related]
20. Modulation of sirtuins: new targets for antiageing.
Pallàs M; Verdaguer E; Tajes M; Gutierrez-Cuesta J; Camins A
Recent Pat CNS Drug Discov; 2008 Jan; 3(1):61-9. PubMed ID: 18221243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
